7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC) Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Chi, KN
  • Hotte, Sebastien
  • Yu, E
  • Tu, D
  • Eigl, B
  • Tannock, I
  • Saad, F
  • North, S
  • Powers, J
  • Eisenhauer, E

publication date

  • September 2009